{'fraction_non_alphanumeric': 0.03666361136571952, 'fraction_numerical': 0.04216315307057745, 'mean_word_length': 5.348837209302325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Circulating CA-195 in hepatocellular carcinoma and metastatic hepatic carcinoma.

This study was conducted to determine the role of a relatively new tumor marker, CA-195, in the diagnosis of hepatocellular carcinoma and metastatic hepatic carcinoma, and in distinguishing between these two conditions. CA-195 levels were measured using a commercially available immunoradiometric assay (Tandem-R CA-195) in 30 black inpatients with hepatocellular carcinoma, 15 metastatic carcinoma, 10 with amoebic liver abscess, 10 with cirrhosis and 10 normal individuals at King Edward VIII Hospital, Durban. A cutt-off value of 10 u/ml was used. The sensitivity and specificity of CA-195 in hepatocellular carcinoma and metastatic carcinoma was 60% and 22%, and 87% and 42% respectively. False positive results occurred in 5 (50%) patients with amoebic liver abscess, 10 (100%) with cirrhosis and 2 (20%) normal individuals. These results indicate this tumor marker as of limited value in the diagnosis of hepatocellular carcinoma and metastatic carcinoma, and in distinguishing between these conditions.